Compare QUALCOMM, Inc. (QCOM) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
QUALCOMM, Inc. vs Recursion Pharmaceuticals Inc — how do they compare? QUALCOMM, Inc. trades at $176.28 (market cap $185.94B), while Recursion Pharmaceuticals Inc trades at $3.24 (market cap $1.86B). The key difference: QUALCOMM, Inc. is far larger — about 100× Recursion Pharmaceuticals Inc's market cap, and QUALCOMM, Inc. pays a 2.11% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| QCOM | RXRX | |
|---|---|---|
Market Cap | $185.94B | $1.86B |
Sector | Technology | Health |
52-Week High | $251.10 | $6.79 |
52-Week Low | $124.07 | $2.84 |
Enterprise Value | $192.90B | $1.38B |
Dividend Yield | 2.11% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Qualcomm (QCOM) trades at $176.4, up 4.54% today, with a bullish technical signal from moving averages and oscillators. The company reported revenue of $44.28B in 2025, with a net income margin of 21.01%. Recent earnings show mixed results, beating estimates in Q4 2025 and Q1 2026 but missing in Q2 2026. Analyst consensus is a Buy with a $200.56 price target, while news highlights AI and data center growth amid smartphone market challenges.
The outlook for QCOM is cautiously optimistic, driven by AI and data center expansion, but near-term risks include smartphone demand softness and margin pressures. Investment opportunity lies in diversification beyond handsets, though competition from Nvidia and Intel poses a threat. Earnings growth and execution on AI initiatives are key catalysts for upside.
RXRX trades at $3.44, down 5.23% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 earnings miss with revenue of $54M and net loss of -$519M, maintaining a negative profit margin of -961.97%. Recent news highlights AI-driven drug discovery progress with Genentech partnership milestones and pipeline expansion in oncology and rare diseases.
Outlook remains speculative with high revenue growth potential from AI platform partnerships offset by persistent losses and cash burn. Investment opportunity hinges on clinical pipeline success, while risks include slow revenue traction and competitive pressures in AI-biotech. Analyst consensus is mixed with 40% buy ratings amid cautious optimism on long-term catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About QUALCOMM, Inc.
Qualcomm develops and licenses wireless technology and designs chips for smartphones. The company's key patents revolve around CDMA and OFDMA technologies, which are standards in wireless communications that are the backbone of all 3G and 4G networks. The firm is a leader in 5G network technology as well. Qualcomm's IP is licensed by virtually all wireless device makers. The firm is also the world's largest wireless chip vendor, supplying nearly every premier handset maker with leading-edge processors. Qualcomm also sells RF-front end modules into smartphones and chips into automotive and Internet of Things markets.
Read more on QCOM →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
